Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2018
SIETES contiene 92588 citas

 
 
 1 a 20 de 3199 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Richard Hobbs FD, McManus RJ. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018:29 de octubre. [Ref.ID 102837]
3. Cita con resumen
AEMPS. Retirada del mercado de algunos lotes de medicamentos que contienen valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:5 de julio. [Ref.ID 102709]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, on behalf of the show SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:9 de junio. [Ref.ID 102692]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L, on behalf of the RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335-45. [Ref.ID 102691]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Blankestijn PJ, Bots ML. Renal denervation in uncontrolled hypertension: the story continues to unfold. Lancet 2018;391:9 de junio. [Ref.ID 102690]
7. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
8. Cita con resumen
Rosich Martí I, Allepuz A, Rodríguez Palomar G, Ortin Font F, Soler Cera M. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. Pharmacoepidemiol Drug Saf 2017;26:91-6. [Ref.ID 101949]
9. Cita con resumen
Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY-J, Lee M-S. ß-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885-7. [Ref.ID 101621]
10. Cita con resumen
Tsai W-C, Wu H-Y, Peng Y-S, Yang J-Y, Chen HY, Chiu Y-L, Hsu S-P, Ko M-J, Pai M-F, Tu Y-K, Hung K-Y, Chien K-L. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:792-9. [Ref.ID 101619]
11.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017;177:966. [Ref.ID 101591]
12.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017;177:955-65. [Ref.ID 101590]
13. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
14. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
15.Tiene citas relacionadas Cita con resumen
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]
17. Cita con resumen
Anónimo. Selexipag (Uptravi) for pulmonary arterial hypertension. Med Lett Drugs Ther 2016;58:21-3. [Ref.ID 100680]
18.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
19.Tiene citas relacionadas Cita con resumen
Anónimo. Atrial fibrillation and stroke: unrecognised and undertreated. Lancet 2016;388:731. [Ref.ID 100608]
20. Cita con resumen
Whittle J. Blood pressure variability and cardiovascular risk. BMJ 2016;354:i4190. [Ref.ID 100604]
Seleccionar todas
 
 1 a 20 de 3199 siguiente >>